Abstract
Background
Radiofrequency ablation (RFA) for the treatment of hepatic tumors has been increasingly used across the United States. Whether treatment-related morbidity has remained low with broader adoption is unclear. We conducted this study to describe in-hospital morbidity associated with RFA for hepatic tumors and to identify predictors of adverse events in a nationally representative database.
Methods
Using the 2006–2009 Nationwide Inpatient Sample, we evaluated all patients aged ≥40 years who underwent an elective RFA for primary or metastatic liver tumors (N = 1298). Outcomes included in-hospital procedure-specific and postoperative complications. Multivariable logistic regression analyses were performed to identify patient and facility predictors of complications.
Results
Most patients underwent a percutaneous (39.9 %) or laparoscopic (22.0 %) procedure for metastatic liver tumors (57.5 %). Procedure-specific complications were frequent (18.2 %), with transfusion requirements (10.7 %), intraoperative bleeding (4.3 %), and hepatic failure (2.8 %) being the most common. Arrhythmias [adjusted odds ratio (AOR) = 1.93 (1.23–3.04)], coagulopathy [AOR = 4.65 (2.95–7.34)], and an open surgical approach [AOR = 2.77 (1.75–4.36)] were associated with an increased likelihood of procedure-specific complications, whereas hospital RFA volume ≥16/year was associated with a reduced likelihood [AOR = 0.59 (0.38–0.91)]. Postoperative complications were also common (12.0 %), with arrhythmias, heart failure, coagulopathy, and open surgical approach acting as significant predictors.
Conclusions
In-hospital morbidity is common after RFA for hepatic tumors. While several patient factors are associated with more frequent procedure-specific complications, treatment at hospitals with an annual volume ≥16 cases/year was associated with a 41 % reduction in the odds of procedure-specific complications.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Reference
Garrean S, Hering J, Saied A, Helton WS, Espat NJ. Radiofrequency ablation of primary and metastatic liver tumors: a critical review of the literature. Am J Surg. 2008;195:508–20.
Curley SA, Marra P, Beaty K, Ellis LM, Vauthey JN, Abdalla EK, et al. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg. 2004;239:450–8.
Krishnamurthy VN, Casillas J, Latorre L. Radiofrequency ablation of hepatic lesions: A review. Appl Radiol. 2003:32:11–26.
El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. New Engl J Med. 1999;340:745–50.
Massarweh NN, Park JO, Farjah F, Yeung RS, Symons RG, Vaughan TL, et al. Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg. 2010;210:441–8.
Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD 3rd, Dorfman GS, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010;28:493–508.
HCUP. Nationwide Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP) 2005–2008. www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed on 6 March 2012.
AHRQ. HCUP Quality control procedures. 2009. http://www.hcup-us.ahrq.gov/db/quality.pdf. Accessed on 6 March 2012.
AHRQ. Comparison reports–nationwide inpatient sample: report #2010-03. 2010. http://www.hcup-us.ahrq.gov/reports/methods/2010_03.pdf. Accessed on 6 March 2012.
Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002;40:IV-43–8.
Kaplan GG, McCarthy EP, Ayanian JZ, Korzenik J, Hodin R, Sands BE. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology. 2008;134:680–7.
Lawthers AG, McCarthy EP, Davis RB, Peterson LE, Palmer RH, Iezzoni LI. Identification of in-hospital complications from claims data. Is it valid? Med Care. 2000;38:785–95.
Borzecki AM, Kaafarani H, Cevasco M, Hickson K, Macdonald S, Shin M, et al. How valid is the AHRQ Patient Safety Indicator “postoperative hemorrhage or hematoma”? J Am Coll Surg. 2011;212:946–53.e1–2.
Utter GH, Zrelak PA, Baron R, Tancredi DJ, Sadeghi B, Geppert JJ, et al. Positive predictive value of the AHRQ accidental puncture or laceration patient safety indicator. Ann Surg. 2009;250:1041–5.
Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. New Engl J Med. 2002;346:1128–37.
Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. New Engl J Med. 2003;349:2117–27.
Mulier S, Mulier P, Ni Y, Miao Y, Dupas B, Marchal G, et al. Complications of radiofrequency coagulation of liver tumours. Br J Surg. 2002;89:1206–22.
Kasugai H, Osaki Y, Oka H, Kudo M, Seki T. Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients. Oncology. 2007;72 Suppl 1:72–5.
Requarth J. Image-guided palliative care procedures. Surg Clin North Am. 2011;91:367–402, ix.
Acknowledgment
Dr. Fox is currently a fellow in the Clinical Scholars Program which is supported by the Robert Wood Johnson Foundation.
Author information
Authors and Affiliations
Corresponding author
Appendix
Rights and permissions
About this article
Cite this article
Fox, J.P., Gustafson, J., Desai, M.M. et al. Short-Term Outcomes of Ablation Therapy for Hepatic Tumors: Evidence from the 2006–2009 Nationwide Inpatient Sample. Ann Surg Oncol 19, 3677–3686 (2012). https://doi.org/10.1245/s10434-012-2397-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-012-2397-0